Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia

Journal of Medicinal Chemistry

Volumn 56, Issue 19, 2013, Pages 7590-7607

  Betschart, Claudia ^a   Hintermann, Samuel ^a   Behnke, Dirk ^a   Cotesta, Simona ^a   Fendt, Markus ^a,e   Gee, Christine E ^a,d   Jacobson, Laura H ^a,g   Laue, Grit ^a   Ofner, Silvio ^a   Chaudhari, Vinod ^b,f   Badiger, Sangamesh ^b   Pandit, Chetan ^b   Wagner, Juergen ^a   Hoyer, Daniel ^a,c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Aurigene Discovery Technologies Limited   (India)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e OTTO VON GUERICKE UNIVERSITY   (Germany)

^f LUPIN LIMITED   (India)

^g UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 [( 1H INDOL 3 YL)METHYL] 9 (4 METHOXYPYRIMIDIN 2 YL) 2,9 DIAZASPIRO[5.5]UNDECAN 1 ONE; ALMOREXANT; HYPNOTIC SEDATIVE AGENT; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; OREXIN RECEPTOR ANTAGONIST; SB 649868; SUVOREXANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; INSOMNIA; MOUSE; NONHUMAN; NONREM SLEEP; SLEEP INDUCTION;

ANIMALS; AZEPINES; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; INDOLES; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; OREXIN RECEPTORS; PYRIMIDINES; QUINOXALINES; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; SLEEP STAGES; SPIRO COMPOUNDS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 84885618102     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4007627     Document Type: Article

References (56)

1. Sakurai, T.; Amemiya, A.; Ishii, M.; Matsuzaki, I.; Chemelli, R. M.; Tanaka, H.; Williams, S. C.; Richardson, J. A.; Kozlowski, G. P.; Wilson, S.; Arch, J. R. S.; Buckingham, R. E.; Haynes, A. C.; Carr, S. A.; Annan, R. S.; Mcnulty, D. E.; Liu, W.-S.; Terrett, J. A.; Elshourbagy, N. A.; Bergsma, D. J.; Yanagisawa, M. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior Cell 1998, 92, 573-585
2. De Lecea, L.; Kilduff, T. S.; Peyron, C.; Gao, X. -B.; Foye, P. E.; Danielson, P. E.; Fukuhara, C.; Battenberg, E. L. F.; Gautvik, V. T.; Bartlett, F. S., II; Frankel, W. N.; Van Den Pol, A. N.; Bloom, F. E.; Gautvik, K. M.; Sutcliffe, J. G. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 322-327
3. Kukkonen, J. P. Physiology of the orexinergic/hypocretinergic system: a revisit in 2012 Am. J. Physiol.: Cell Physiol. 2013, 304, C2-32
4. Zhang, X. Y.; Yu, L.; Zhuang, Q. X.; Zhu, J. N.; Wang, J. J. Central functions of the orexinergic system Neurosci. Bull. 2013, 29, 355-365
5. Tsujino, N.; Sakurai, T. Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system Pharmacol. Rev. 2009, 61, 162-176
6. Scammell, Th. E.; Winrow, Ch. J. Orexin receptors: pharmacology and therapeutic opportunities Annu. Rev. Pharmacol. Toxicol. 2011, 51, 243-266
7. Chemelli, R. M.; Willie, J. T.; Sinton, Ch. M.; Elmquist, J. K.; Scammell, T.; Lee, Ch.; Richardson, J. A.; Williams, S. C.; Xiong, Y.; Kisanuki, Y.; Fitch, T. E.; Nakazato, M.; Hammer, R. E.; Saper, C. B.; Yanagisawa, M. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation Cell 1999, 98, 437-451
8. Kalogiannis, M.; Grupke, S. L.; Potter, P. E.; Edwards, J. G.; Chemelli, R. M.; Kisanuki, Y. Y.; Yanagisawa, M.; Leonard, C. S. Narcoleptic orexin receptor knockout mice express enhanced cholinergic properties in laterodorsal tegmental neurons Eur. J. Neurosci. 2010, 32, 130-142
9. Morawska, M.; Buchi, M.; Fendt, M. Narcoleptic episodes in orexin-deficient mice are increased by both attractive and aversive odors Behav. Brain Res. 2011, 222, 397-400
10. Sakurai, T. Orexin deficiency and narcolepsy. Curr. Opin. Neurobiol. [Online early access]. DOI: http://dx.doi.org/10.1016/j.conb.2013.04.007. Published Online: May 7, 2013.
11. Lin, L.; Faraco, J.; Li, R.; Kadotani, H.; Rogers, W.; Lin, X.; Qiu, X.; De Jong, P. J.; Nishino, S.; Mignot, E. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene Cell 1999, 98, 365-376
12. Thannickal, T. C.; Moore, R. Y.; Nienhuis, R.; Ramanathan, L.; Gulyani, S.; Aldrich, M.; Cornford, M.; Siegel, J. M. Reduced number of hypocretin neurons in human narcolepsy Neuron 2000, 27, 469-474
13. Nishino, S.; Ripley, B.; Overeem, S.; Lammers, G. J.; Mignot, E. Hypocretin (orexin) deficiency in human narcolepsy Lancet 2000, 355, 39-40
14. Hagan, J. J.; Leslie, R. A.; Patel, S.; Evans, M. L.; Wattam, T. A.; Holmes, S.; Benham, C. D.; Taylor, S. G.; Routledge, C.; Hemmati, P.; Munton, R. P.; Ashmeade, T. E.; Shah, A. S.; Hatcher, J. P.; Hatcher, P. D.; Jones, D. N.; Smith, M. I.; Piper, D. C.; Hunter, A. J.; Porter, R. A.; Upton, N. Orexin A activates locus coeruleus cell firing and increases arousal in the rat Proc. Natl. Acad. Sci. U.S.A. 1999, 96 (19) 10911-10916
15. Lee, M. G.; Hassani, O. K.; Jones, B. E. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle J. Neurosci. 2005, 25, 6716-6720
16. Alam, M. N.; Gong, H.; Alam, T.; Jaganath, R.; McGinty, D.; Szymusiak, R. Sleep-waking discharge patterns of neurons recorded in the rat perifornical lateral hypothalamic area J. Physiol. 2002, 538, 619-631
17. Peyron, C.; Tighe, D. K.; van den Pol, A. N.; de Lecea, L.; Heller, H. C.; Sutcliffe, J. G.; Kilduff, T. S. Neurons containing hypocretin (orexin) project to multiple neuronal systems J. Neurosci. 1998, 18, 9996-19915
18. Gotter, A. L.; Roecker, A. J.; Hargreaves, R.; Coleman, P. J.; Winrow, C. J.; Renger, J. J. Orexin receptors as therapeutic drug targets Prog. Brain Res. 2012, 198, 163-188
19. Nishino, S. The hypocretin/orexin receptor: therapeutic prospective in sleep disorders Expert Opin. Invest. Drugs 2007, 16, 1785-1797
20. Coleman, P. J.; Cox, Ch. D.; Roecker, A. J. Discovery of dual orexin receptor antagonists (DORAs) for the treatment of insomnia Curr. Top. Med. Chem. 2011, 11, 696-725
21. Gatfield, J.; Brisbane-Roch, C.; Jenck, F.; Boss, Ch. Orexin receptor antagonists: a new concept in CNS disorders? ChemMedChem 2010, 5, 1197-1214
22. Lebhod, T. P.; Bonaventura, P.; Shireman, B. T. Selective orexin receptor antagonists Bioorg. Med. Chem. Lett. 2013, 23, 4761-4769
23. Brisbare-Roch, C.; Dingemanse, J.; Koberstein, R.; Hoever, P.; Aissaoui, H.; Flores, S.; Mueller, C.; Nayler, O.; van Gerven, J.; de Haas, S. L.; Hess, P.; Qiu, C.; Buchmann, S.; Scherz, M.; Weller, T.; Fischli, W.; Clozel, M.; Jenck, F. Promotion of sleep by targeting the orexin system in rats, dogs and humans Nat. Med. (N.Y., NY, U.S.) 2007, 13, 150-155
24. Hoever, P.; de Haas, S.; Winkler, J.; Schoemaker, R. C.; Chiossi, E.; van Gerven, J.; Dingemanse, J. Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant Clin. Pharmacol. Ther. (N.Y., NY, U.S.) 2010, 87, 593-600
25. Winrow, Ch. J.; Gotter, A. L.; Cox, Ch. D.; Doran, S. M.; Tannenbaum, P. L.; Breslin, M. J.; Garson, S. L.; Fox, S. V.; Harrell, Ch. M.; Stevens, J.; Reiss, D. R.; Cui, D.; Coleman, P. J.; Renger, J. J. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist J. Neurogenet. 2011, 25, 52-61
26. Bettica, P.; Nucci, G.; Pyke, C.; Squassante, L.; Zamuner, S.; Ratti, E.; Gomeni, R.; Alexander, R. Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist J. Psychopharmacol. 2012, 26, 1058-1070
27. Sun, H.; Kennedy, W. P.; Wilbraham, D.; Lewis, N.; Calder, N.; Li, X.; Ma, J.; Yee, K. L.; Ermlich, S.; Mangin, E.; Lines, C.; Rosen, L.; Chodakewitz, J.; Murphy, G. M. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men Sleep 2013, 36 (2) 259-267
28. Willie, J. T.; Chemelli, R. M.; Sinton, Ch. M.; Tokita, S.; Williams, S. C.; Kisanuki, Y. Y.; Marcus, J. N.; Lee, Ch.; Elmquist, J. K.; Kohlmeier, K. A.; Leonard, Ch. S.; Richardson, J. A.; Hammer, R. E.; Yanagisawa, M. Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes Neuron 2003, 5, 715-730
29. Mang, G. M; Duerst, Th.; Buerki, H.; Imobersteg, S.; Abramowski, D.; Schuepbach, E.; Hoyer, D.; Fendt, M.; Gee, Ch. E. The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors Sleep 2012, 35, 1625-1635
30. Gozzi, A.; Turrini, G.; Piccoli, L.; Massagrande, M.; Amantini, D.; Antolini, M.; Martinelli, P.; Cesari, N.; Montanari, D.; Tessari, M.; Corsi, M.; Bifone, A. Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists PLoS One 2011, 6, e16406
31. Dugovic, Ch.; Shelton, J. E.; Aluisio, L. E.; Fraser, I. C.; Jiang, X.; Sutton, S. W.; Bonaventure, P.; Yun, S.; Li, X.; Lord, B.; Dvorak, C. A.; Carruthers, N. I.; Lovenberg, T. W. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat J. Pharmacol. Exp. Ther. 2009, 330, 142-151
32. Kummangal, B. A.; Kumar, D.; Mallick, H. N. Intracerebroventricular injection of orexin-2 receptor antagonist promotes REM sleep Behav. Brain Res. 2013, 237, 59-62
33. Steiner, M. A.; Gatfield, J.; Brisbane-Roch, C.; Dietrich, H.; Treiber, A.; Jenck, F.; Boss, Ch. Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist ChemMedChem 2013, 8, 898-903
34. Morairty, S. R.; Revel, F. G.; Malherbe, P.; Moreau, J. L.; Valladao, D.; Wettstein, J. G.; Kilduff, T. S.; Borroni, E. Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone PLoS One 2012, 7, e39131
35. Smith, M. I.; Piper, D. C.; Duxon, M. S.; Upton, N. Evidence implicating a role for orexin-I receptor modulation of paradoxical sleep in the rat Neurosci. Lett. 2003, 341, 256-258
36. Mieda, M.; Hasegawa, E.; Kisanuki, Y. Y.; Sinton, C. M.; Yanagisawa, M.; Sakurai, T. Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep J. Neurosci. 2011, 31, 6518-6526
37. Chen, L.; McKenna, J. T.; Bolortuya, Y.; Winston, S.; Thakkar, M. M.; Basheer, R.; Brown, R. E.; McCarley, R. W. Knockdown of orexin type 1 receptor in rat locus coeruleus increases REM sleep during the dark period Eur. J. Neurosci. 2010, 32, 1528-1536
38. Di Fabio, R.; Pellacani, A.; Faedo, S.; Roth, A.; Piccoli, L.; Gerrard, P.; Porter, R. A.; Johnson, Ch. N.; Thewlis, K.; Donati, D.; Stasi, L.; Spada, S.; Stemp, G.; Nash, D.; Branch, C.; Kindon, L.; Massagrande, M.; Poffe, A.; Braggio, S.; Chiarparin, E.; Marchioro, C.; Ratti, E.; Corsi, M. Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders Bioorg. Med. Chem. Lett. 2011, 21, 5562-5567
39. Breslin, M. J.; Cox, Ch. D.; Whitman, D. B. Preparation of Diazaspirodecane Derivatives As Orexin Receptor Antagonists. PCT Int. Appl. WO 2007025069 A2 20070301, 2007.
40. Fujimoto, T.; Tomata, Y.; Kunimoto, J.; Hirozane, M.; Marui, S. Discovery of spiropiperidine-based potent and selective orexin-2 receptor antagonists Bioorg. Med. Chem. Lett. 2011, 21, 6409-6413
41. Cox, Ch. D.; Breslin, M. J.; Whitman, D. B.; Schreier, J. D.; McGaughey, G. B.; Bogusky, M. J.; Roecker, A. J.; Mercer, S. P.; Bednar, R. A.; Lemaire, W.; Bruno, J. G.; Reiss, D. R.; Harrell, C. M.; Murphy, K. L.; Garson, S. L.; Doran, S. M.; Prueksaritanont, T.; Anderson, W. B.; Tang, C.; Roller, S.; Cabalu, T. D.; Cui, D.; Hartman, G. D.; Young, S. D.; Koblan, K. S.; Winrow, Ch. J.; Renger, J. J.; Coleman, P. J. Discovery of the dual orexin receptor antagonist [(7 R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl] [5-methyl-2-(2 H -1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia J. Med. Chem. 2010, 53, 5320-5332
42. Cox, Ch. D.; McGaughey, G. B.; Bogusky, M. J.; Whitman, D. B.; Ball, R. G.; Winrow, Ch. J.; Renger, J. J.; Coleman, P. J. Conformational analysis of N,N-disubstituted-1,4-diazepane orexin receptor antagonists and implications for receptor binding Bioorg. Med. Chem. Lett. 2009, 19, 2997-3001
43. Coleman, P. J.; Schreier, J. D.; McGaughey, G. B.; Bogusky, M. J.; Cox, Ch. D.; Hartman, G. D.; Ball, R. G.; Harrell, C. M.; Reiss, D. R.; Prueksaritanont, Th.; Winrow, Ch. J.; Renger, J. J. Design and synthesis of conformationally constrained N,N-disubstituted 1,4-diazepanes as potent orexin receptor antagonists Bioorg. Med. Chem. Lett. 2010, 20, 2311-2315
44. Coleman, P. J.; Schreier, J. D.; Roecker, A. J.; Mercer, S. P.; McGaughey, G. B.; Cox, Ch. D.; Hartman, G. D.; Harrell, C. M.; Reiss, D. R.; Doran, S. M.; Garson, S. L.; Anderson, W. B.; Tang, C.; Prueksaritanont, Th.; Winrow, Ch. J.; Renger, J. J. Discovery of 3,9-diazabicyclo[4.2.1]nonanes as potent dual orexin receptor antagonists with sleep-promoting activity in the rat Bioorg. Med. Chem. Lett. 2010, 20, 4201-4205
45. Coleman, P. J.; Schreier, J. D.; Cox, Ch. D.; Breslin, M. J.; Whitman, D. B.; Bogusky, M. J.; McGaughey, G. B.; Bednar, R. A.; Lemaire, W.; Doran, S. M.; Fox, S. V.; Garson, S. L.; Gotter, A. L.; Harrell, C. M.; Reiss, D. R.; Cabalu, T. D.; Cui, D.; Prueksaritanont, Th.; Stevens, J.; Tannenbaum, P. L.; Ball, R. G.; Stellabott, J.; Young, S. D.; Hartman, G. D.; Winrow, Ch. J.; Renger, J. J. Discovery of [(2 R,5 R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin- 1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties ChemMedChem 2012, 7, 415-425
46. Gracias, V.; Gasiecki, A. F.; Moore, J. D.; Akritopoulou-Zanze, I.; Djuric, S. W. An expedient route to diaza-spirocycles utilizing a sequential multicomponent α-aminoallylation/ring-closing metathesis strategy Tetrahedron Lett. 2006, 47, 8977-8980
47. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6 (11) 881-890
48. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9 (10) 430-431
49. Maurer, T. S.; DeBartolo, D. B.; Tess, D. A.; Scott, D. O. Relationship between exposure and non-specific binding of thirty-three central nervous system drugs in mice Drug Metab. Dispos. 2005, 33, 175-181
50. Pack, A. I.; Galante, R. J.; Maislin, G.; Cater, J.; Metaxas, D.; Lu, S.; Zhang, L.; Von Smith, R.; Kay, T.; Lian, J.; Svenson, K.; Peters, L. L. Novel method for high-throughput phenotyping of sleep in mice Physiol. Genomics 2007, 28 (2) 232-238
51. Herring, W. J.; Snyder, E.; Budd, K.; Hutzelmann, J.; Snavely, D.; Liu, K.; Lines, Ch.; Roth, T.; Michelson, D. Orexin receptor antagonism for treatment of insomnia-A randomized clinical trial of insomnia Neurology 2012, 79, 2265-2274
52. Bettica, P.; Squassante, L.; Groeger, J. A.; Gennery, B.; Winsky-Sommerer, R.; Dijk, D. J. Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia Neuropharmacology 2012, 1-10
53. 2 orexin receptor antagonists Eur. J. Pharmacol. 2012, 692, 1-9
54. 2 antagonists Mol. Pharmacol. 2009, 76, 618-631
55. Jiang, X.-H.; Song, Y.-L.; Long, Y.-Q. Facile synthesis of 4-substituted-4-aminopiperidine derivatives, the key building block of piperazine-based CCR5 antagonists Bioorg. Med. Chem. Lett. 2004, 14, 3675-3678
56. Badiger, S.; Behnke, D.; Betschart, C.; Chaudhari, V.; Cotesta, S.; Hintermann, S.; Lerchner, A.; Limam, F.; Ofner, S.; Pandit, C.; Wagner, J. Di/tri-aza-spiro-C9-C11alkanes. US20120165331, 2012.